



A New Paradigm in Oral Drug Delivery with the Precision Timed Release™ Platform

Cingulate | Corporate Presentation
2Q 2026



Forward-Looking Statements

This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature.

These statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2025. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

Why Cingulate (Nasdaq: CING)

Near-Term Catalysts = Market Opportunity

- CTx-1301 Commercial Launch planned 1H 2027
- 100 million prescriptions in \$10Bn target market
- Clear Differentiation with Unprecedented Clinical Data
- Leadership Team with 90+ years of ADHD Experience

Long-Term Catalysts = Value Creation through PTR™ Platform Pipeline

ADDITIONAL VALIDATION

- Recent Close of \$12M (up to \$21.6M) strategic & long-term investment
- Cash runway to anticipated approval ; Cash runway to launch with available tools
- Commercial launch preparation on track encompassing all big pharma functions

CINGULATE LEADERSHIP TEAM



Shane J Schaffer
Chief Executive Officer

- **Pharmaceutical Executive Leader:** 30+ years in CEO, Board of Director, and diverse roles across biotech & pharma. Doctor of Pharmacy. Cingulate Co-Founder.
- **Commercialization Expert:** billion-dollar brands including the ADHD Franchise of Ritalin® & Focalin®, Lipitor®, Lyrica®, Eligard®, Arixtra®, Hyalgan® and Avapro®/Avalide®.
- **Corporate & Organizational Leader:** Spearheaded entire Cingulate organization; Capital raised \$150M+



Jennifer Callahan
Chief Financial Officer

- **Experienced Financial Leader:** 30+ years in accounting and financial management across a variety of industries.
- **A Decade of Experience in Life Sciences** as VP of Finance and Chief Financial Officer with Mini-MBA in BioPharma Innovation from Rutgers University
- **Strategic Advisor:** Expert in process improvement, system implementation, budgeting, due diligence, and organizational development.



Bryan Downey
Chief Commercial Officer

- **Broad Industry & Academic Background:** Led portfolios in multiple therapeutic areas at levels of increasing responsibility; BS and MS degrees from Texas A&M – Kingsville and an MBA from Cornell.
- **Seasoned C-Suite Executive:** 20+ years in CEO, President, Board and variety of commercial roles at major pharma companies, driving strategy and growth.
- **Leadership Development Expert:** Former Managing Director at CRA | Admired Leadership®, coaching /advising on transformation and transitions.



Matthew Brams, MD
Chief Medical Officer

- **Extensive Clinical & Research Experience:** Over 25 years in psychiatry with a focus on ADHD and Autism; led 125+ clinical trials.
- **Leader in Drug Development:** Co-founded Cingulate Therapeutics; contributed to FDA approval of 15+ CNS drugs.
- **Academic & Professional Recognition:** Clinical Associate Professor at Baylor; published 20+ articles; Senior Board Examiner for ABPN.



Raul Silva, MD
Chief Science Officer

- **Experienced Psychiatric Leader:** Practicing child and adolescent psychiatrist with leadership roles at NYU, Bellevue Hospital, and Rockland Children's Psychiatric Center.
- **Extensive Academic Contributions:** Author of 125+ publications, speaker at 120+ events, and researcher on 21 projects.
- **Advanced Training & Certification:** Completed fellowships at Columbia and NYU; board-certified in general and child/adolescent psychiatry.



Nilay Patel
Chief Legal Officer

- **Broad Pharma Legal/Compliance Expertise:** 20+ years in the pharma/biotech industry across all stages of development and commercialization
- **Recent ADHD Experience:** Helped build infrastructure to commercialize ADHD product in United States
- **M&A Experience:** Partnered with CEO, investment bankers and transaction counsel to close acquisition of Ironshore Pharmaceuticals for \$550M.




The Near-Term Opportunity

CTx-1301 in US ADHD Market

- Over 100 Million Prescriptions
- Significant Unmet Needs and Dissatisfaction with Current Treatments

The Market Opportunity



* Not indicating CTx-1301 Pricing
Source: NPA Data; Sept 2025

The Problem: Where Today's ADHD Therapies May Fall Short

What Does Differentiation Look Like?

ADHD BRANDS	APPROVED	ATTRIBUTES ¹		UNMET NEEDS ¹			
		Onset (hr)	Duration (less onset)	Fast Onset of Action ≤ 30 min	Entire Active-Day Efficacy*	Minimize Crash/Rebound	Avoid Booster ¹
Vyvanse®	2007	1 ½ - 2	8-9 hours	✗	✗	✗	✗
Adderall® XR	2001	1 ½	7-8 hours	✗	✗	✗	✗
Concerta®	2000	2	6-7 hours	✗	✗	✗	✗
Focalin® XR	2005	½	7-8 hours	✓	✗	✗	✗
CTx-1301	2026 Anticipated Approval	½	12 hours	✓	✓	✓	✓

92%
of ALL Extended Release Stimulant Rx's³

60%
use short-acting 'booster' dose every day!²



* Entire-active day efficacy defined as less than or equal to a 30 min onset of action with true 12 hours of duration vs. baseline

¹ Information based upon product Package Inserts, and Summary Basis of Approvals for the approved products in chart and Ann C. Childress, Nathalie Beltran, Carl Supnet & Margaret D. Weiss (2021) Reviewing the role of emerging therapies in the ADHD armamentarium, Expert Opinion on Emerging Drugs, 26:1, 1-16.

² Outside the Box: Rethinking ADD/ADHD in Children and Adults A Practical Guide; First Edition, p. 185 Thomas E. Brown, PhD

³ NPA Data. 12-months rolling through Sept 2023

Recent Launches Lack Meaningful Clinical Innovation


ADHD BRANDS	ATTRIBUTES ¹		UNMET NEEDS			
Product	Onset	Duration	Fast Acting (≤ 30 min)	Entire Active-Day Efficacy*	Avoid Crash/Rebound	Avoid Booster
Quillivant / Chew® XR	60 mins	8 hours	✗	✗	✗	✗
Mydayis®	2 or 4 hrs	16+ hours	✗	✗	✗	✗
Adzenys® ER/ODT	60 mins	8-9 hours	✗	✗	✗	✗
Cotempla® XR/ODT	60 mins	10-12 hours	✗	✗	✗	✗
Aptensio® XR	60 mins	9 hours	✗	✗	✗	✗
Evekeo® / ODT	60 mins	10 hours	✗	✗	✗	✗
Dynavel® XR Oral Susp.	60 min	13 hours	✗	✗	✗	✗
Zenzedi®	60 mins	4-5 hours	✗	✗	✗	✗
Jornay® PM (at night)	2-hour window	10-11 hours	✗	✗	✗	✗
Adhansia® XR – <i>Discontinued</i>	60 mins	12-13 hours	✗	✗	✗	✗
Azstarys® (summer 2021)	Failed Endpoint	Failed Endpoint	✗	✗	✗	✗

* Entire-active day efficacy defined as less than or equal to a 30 min onset of action with 14-16 hours of duration vs. placebo

¹ Information based upon product Package Inserts and Summary Basis of Approvals and Ann C. Childress, Nathalie Beltran, Carl Supnet & Margaret D. Weiss (2021) Reviewing the role of emerging therapies in the ADHD armamentarium, Expert Opinion on Emerging Drugs, 26:1, 1-16.

Focus had to be on groundbreaking delivery technology

Precision Timed Release™ (PTR™) Platform Unlocks the Possibility for 'True' Once-daily, Multi-dose Tablets



[See the PTR™ Platform in Action @ Cingulate.com](https://www.cingulate.com)




The Solution

Clinical Evidence


One Product Designed to Overcome All Unmet Needs

Entire Active-Day Efficacy, Stop the Crash & Rebound, Eliminate Booster Doses



Subject ID: 01-510

PERMP – Adult Laboratory Classroom




Data on file, Cingulate Inc. 1301-022 NCT 05631626

CTx-1301 PERMP Effect Size over Entire Active Day

A Meta-Analysis conducted by Faraone and Glatt (Clin Psych 71:6 June 2010)¹ using 11 published studies with long-acting stimulants in adults demonstrated the **Average Stimulant Effect Size to be 0.73** (approximate range 0.5 to 0.9).¹

CTx-1301 Average Effect Size: 1.79



R
A
N
G
E

CTx-1301 Demonstrated Significantly Lower Adverse Events

28.6% reduction in TEAE's related to CTx-1301 versus Focalin XR (14.3% difference)

	Focalin XR 5 mg (n=41)	CTx-1301 6.25 mg (n=39)	Focalin XR 40 mg (n=43)	CTx-1301 50 mg (n=42)	All CTx-1301 (n=42)	All Focalin XR (n=44)
Patients with at least one						
Treatment Emergent Adverse Events	7 (17.1%)	4 (10.3%)	22 (51.2%)	14 (33.3%)	17 (40.5%)	25 (56.8%)
Mild	7 (17.1%)	4 (10.3%)	20 (46.5%)	14 (33%)	17 (40.5%)	23 (52.3%)
Moderate	0	0	2 (4.7%)	0	0	2 (4.5%)
Severe	0	0	0	0	0	0
TEAE Related to Study Drug	5 (12.2%)	3 (7.7%)	20 (46.5%)	13 (31.0%)	15 (35.7%)	22 (50.0%)
AE Leading to Study or Drug Withdrawal	1 (2.4%)	0	1 (2.3%)	0	0	2 (4.5%)

There were no serious adverse events.

Source: CSR CTx-1301-001 Listing 16.2.7.1

The ADHD Medication Providing Daily Durability

Precision Timed Release™ (PTR™) Platform Unlocks the Possibility for 'True' Once-daily, Multi-dose Tablets




\$10 Bn Opportunity

Dominated by Stimulants

Over 100 Million Stimulant Prescriptions*

*NPA Data. 12-months rolling through Sept 2025





How Cingulate Achieves It

Commercialization & Go-To-Market Strategy

Cingulate Driven Commercialization

Leveraging Best in Industry Partners



Launch Ready with Best in Industry Commercialization

Essential Factors To Drive Demand

1. Reimbursement

- Payer Research indicates Positive Acceptance for Reimbursement
- Pricing & Contracting to Maximize GTN and 'Lives Covered'
- Launch Plan includes Seamless Coverage at Point of Sale (Cover My Meds, Voucher, etc.)

2. Best-In-Class Product


- Unprecedented Entire Active-Day Efficacy
- Overcomes 8+ Current Unmet Medical Needs (duration, onset, boosters, abuse/diversion, available dosage strengths, tolerability...)
- First ADHD product to launch with data in Adults and Children

3. Share of Voice


- ADHD category has high SOV sensitivity
- Proper FFE process to ensure Reach & Frequency Achievement
- Unparalleled combination of Personal & Non-Personal Promotion with Sales Team, Omnichannel, and formulary access

Cingulate Sales Professional Team:


- 110 – 120 FTEs at Launch
 - 25-40 Sales Professionals at launch
 - **Invisage**TM Omnichannel adds 80 FTEs



Pressure Testing Cingulate's G2M Strategy



Go To Market Execution – Implementing the Entire Big Pharma Toolbox



Research Shows Favorable Reimbursement Potential

Executive Summary of Qualitative Findings (July 2, 2024): ~122M covered lives

- CTx-1301 was rated most valuable versus Vyvanse, Adderall XR, Concerta, Focalin XR, Azstarys, and Qelbree.
- CTx-1301 is likely to gain Commercial and Medicaid coverage as a Preferred brand without restrictions or a Non-Preferred brand with 1-2 steps (typical in ADHD) all dependent on rebate ranges
- Contracting and pricing estimates yielded a WAC & Rebate range that is favorable to Cingulate's current forecast models.

4 brands drive this market... All have generic equivalents... The BRANDS make \$2Bn+ per year!




Path to Market

Milestones
Capital

Path to Market

Near-term Milestones Driving 12-Month Value



Funding Outlook:

- 9+ months cash on hand
- Mix of Royalty – Debt – Equity Capital



The Future

Vast Pipeline Opportunities via PTR™ Platform

PTR Facilitates a Potential Pipeline Addressing Multiple Indications

Identified Targets for PTR™ Platform Pipeline Significant Unmet Needs in Billion Dollar Markets

In Development

- ADHD (CTx-1301, 1302)
- Anxiety (CTx-2103)

Near-Term Targets Identified

- Insomnia
- Depression
- Bipolar Disorder
- Movement Disorders
- Cardiovascular Disorders
- Xerostomia (dry mouth)

Future Therapeutic Areas

- Migraine
- Hypothyroidism
- Oral Oncology Medicines
- Psychosis
- Alzheimer's Disease
- Pain (Non-Opioid)



Thank You

